 |
|
Where tumor cells boldly go: Weill Cornell cancer biologists shed light on the metastatic niche
May 04, 2009Researchers foresee a wave of new cancer R&D that targets changes in tissues far from the primary tumor
Traditionally, cancer biologists have embraced a simple and direct model of the disease process: The tumor -- the "seed" -- was seen as bearing total responsibility for the spread of cancer to distant tissues -- the "soil" in which the seed embedded itself, grew, and reproduced. The result was a seed-dominant model that determined the way doctors treated cancer, using strategies targeting the tumor seed but neglecting the role of the soil.
Recently, however, some researchers have been focusing on the permissive microenvironment, or the metastatic niche, that forms in particular tissues located far from the primary tumor, well before full metastasis takes hold.
"In cancer, it is metastatic disease that causes morbidity and mortality," says Dr. David Lyden, co-author of an article in the April 2009 issue of Nature Reviews Cancer.
"At our lab, we're developing a strategic approach to studying metastasis. Our goal is ultimately to be able to predict and pre-empt the process -- early, if possible, but even in advanced metastasis," adds Dr. Lyden, the Stavros S. Niarchos Associate Professor in Pediatric Cardiology, an investigator in the Division of Pediatric Hematology and Oncology, and associate professor of cell and development biology at Weill Cornell Medical College.
Led by Dr. Lyden, a team of researchers is looking at the molecular and cellular players that mediate changes at future sites of metastasis such as liver, lung, brain or bone, and thereby direct the migration patterns of tumor cells.
The group has zeroed in on several of these essential players, including bone marrow-derived cells and growth factors secreted by the tumor itself. These, Dr. Lyden explains, instruct the pre-metastatic niche to get ready for a long visit, one that will require comfortable accommodations for a rapidly growing population of permanent guests.
If the pre-metastatic niche does the tumor's bidding and boosts production of inflammatory chemokines and fibronectin, among other cancer-friendly proteins, a secondary tumor has a good chance of forming -- and thriving.
Dr. Lyden believes his lab's discoveries could open doors leading to the development of new cancer treatments that target each step along the metastatic pathway. "We can envision a time in the not-too-distant future when we'll be able to prevent metastasis through a new approach for early detection and treatment," he says. "That's why we're studying the earliest changes in the pre-metastatic niche in such depth.
"At the same time," he continues, "the challenge is to understand metastasis in its entirety by familiarizing ourselves with the shifting molecular and cellular microenvironment at each step along the way. The ramifications of this approach for cancer treatment, we believe, are inestimable."
The Lyden lab at Weill Cornell was one of seven to be represented in the current issue of Nature Reviews, which is devoted exclusively to the subject of cancer metastasis in a special issue. In their article titled "The Metastatic Niche: Adapting the Foreign Soil," Dr. Lyden and lead author Dr. Bethan Psaila, a Fulbright Fellow in the Lyden lab, summarize the discoveries and insights they've gleaned over the past decade.
"The 'seed and soil' hypothesis is considered one of the most important among cancer biologists, but our lab -- especially in collaboration with Dr. Rosandra Kaplan and the lab of Dr. Shahin Rafii -- was actually first to address it in real terms," Dr. Lyden says. "Now, many other labs are moving in this direction, and all of them are opening up highly promising new avenues for inquiry."
Preventing and treating cancerous tumors will continue to be central to cancer treatment strategy, he adds. But soon, we may begin to see new strategies aimed at disarming the real killer: metastatic disease.
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
"In cancer, it is metastatic disease that causes morbidity and mortality," says Dr. David Lyden, co-author of an article in the April 2009 issue of Nature Reviews Cancer.
"At our lab, we're developing a strategic approach to studying metastasis. Our goal is ultimately to be able to predict and pre-empt the process -- early, if possible, but even in advanced metastasis," adds Dr. Lyden, the Stavros S. Niarchos Associate Professor in Pediatric Cardiology, an investigator in the Division of Pediatric Hematology and Oncology, and associate professor of cell and development biology at Weill Cornell Medical College.
Led by Dr. Lyden, a team of researchers is looking at the molecular and cellular players that mediate changes at future sites of metastasis such as liver, lung, brain or bone, and thereby direct the migration patterns of tumor cells.
The group has zeroed in on several of these essential players, including bone marrow-derived cells and growth factors secreted by the tumor itself. These, Dr. Lyden explains, instruct the pre-metastatic niche to get ready for a long visit, one that will require comfortable accommodations for a rapidly growing population of permanent guests.
If the pre-metastatic niche does the tumor's bidding and boosts production of inflammatory chemokines and fibronectin, among other cancer-friendly proteins, a secondary tumor has a good chance of forming -- and thriving.
Dr. Lyden believes his lab's discoveries could open doors leading to the development of new cancer treatments that target each step along the metastatic pathway. "We can envision a time in the not-too-distant future when we'll be able to prevent metastasis through a new approach for early detection and treatment," he says. "That's why we're studying the earliest changes in the pre-metastatic niche in such depth.
"At the same time," he continues, "the challenge is to understand metastasis in its entirety by familiarizing ourselves with the shifting molecular and cellular microenvironment at each step along the way. The ramifications of this approach for cancer treatment, we believe, are inestimable."
The Lyden lab at Weill Cornell was one of seven to be represented in the current issue of Nature Reviews, which is devoted exclusively to the subject of cancer metastasis in a special issue. In their article titled "The Metastatic Niche: Adapting the Foreign Soil," Dr. Lyden and lead author Dr. Bethan Psaila, a Fulbright Fellow in the Lyden lab, summarize the discoveries and insights they've gleaned over the past decade.
"The 'seed and soil' hypothesis is considered one of the most important among cancer biologists, but our lab -- especially in collaboration with Dr. Rosandra Kaplan and the lab of Dr. Shahin Rafii -- was actually first to address it in real terms," Dr. Lyden says. "Now, many other labs are moving in this direction, and all of them are opening up highly promising new avenues for inquiry."
Preventing and treating cancerous tumors will continue to be central to cancer treatment strategy, he adds. But soon, we may begin to see new strategies aimed at disarming the real killer: metastatic disease.
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Metastasis Current Events and Metastasis News RSSExperimental agent reduces breast cancer metastasis to bone
Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer.
Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results.
MicroRNA-mediated metastasis suppression
Metastases are responsible for over 90% of cancer deaths. In the upcoming issue of G&D, Dr. Robert Weinberg (MIT) and colleagues lend molecular insight into how microRNAs suppress tumor metastasis.
Is short-term Celecoxib intervention a effective method for preventing gastric carcinogenesis?
Since the isolation and culture of Helicobacter pylori (H. pylori) in 1983, this bacterium has become accepted as an important human pathogen for the development of gastritis, peptic ulcer, and gastric cancer.
A case of post-gastrectomy acute pancreatitis
Gastrectomy is commonly performed for both benign and malignant lesions. Although the incidence of post-gastrectomy acute pancreatitis (PGAP) is low compared to other well-recognized post-operative complications, it has been reported to be associated with a high mortality rate.
Bioluminescence imaging used for eye cancer detection
At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.
KEAP1 Keeps major cancer-promoting protein at bay
A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell.
NEDD9 Protein Supports Growth of Aggressive Breast Cancer
Researchers at Fox Chase Cancer Center have demonstrated that a protein called NEDD9 may be required for some of the most aggressive forms of breast cancer to grow. Their findings, based on the study of a mouse model of breast cancer, are presented in a recent issue of Cancer Research, available on-line now.
Gerton Lab determines the composition of centromeric chromatin
The Stowers Institute's Gerton Lab has provided new evidence to clarify the structure of nucleosomes containing Cse4, a centromere-specific histone protein required for proper kinetochore function, which plays a critical role in the process of mitosis. The work, conducted in yeast cells, was published in the most recent issue of Molecular Cell.
Ultrasound can predict tumor burden and survival in melanoma patients
Researchers have shown for the first time that patterns of ultrasound signals can be used to identify whether or not cancer has started to spread in melanoma patients, and to what extent. The discovery enables doctors to decide on how much surgery, if any, is required and to predict the patient's probable survival.
More Metastasis Current Events and Metastasis News Articles
 |
Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice by Venkateshwar Keshamouni (Editor), Douglas Arenberg (Editor), Gregory Kalemkerian (Editor) Lung cancer is the leading cause of cancer-related mortality. Metastatic lung cancer is responsible for more than ninety percent of lung cancer related deaths. However, relatively little progress has been made in understanding the process of lung cancer metastasis. The two main aims of this book are a) to introduce clinical aspects to basic scientists and basic molecular and cellular concepts to clinical investigators, in order to promote collaboration and foster much needed translational research; and b) to introduce new and emerging concepts and approaches in metastasis research to lung cancer research community at large. In this attempt, the book will cover a broad spectrum of subjects ranging from the current trends in the clinical management of the metastatic... |
 |
Xenakis: Metastasis; Pithoprakta; Eonta Iannis Xenakis (Composer), Maurice Le Roux (Composer), Ensemble Instrumental de Musique Contemporaine de Paris (Composer), ORTF National Orchestra (Composer), Yuji Takahashi (Composer), G. Moisan (Composer), J. Toulon (Composer), M. Chapellier (Composer), L. Longo (Composer), Pierre Thibaud (Composer) |
 |
Metastasis Arturo Tamayo Orchestre Philharmonique du Luxembourg (Primary Contributor) |
 |
Quick FACTS Bone Metastasis (Quickfacts) by American Cancer Society (Author) A staggering 5.8 million males and 5 million females worldwide are diagnosed with cancer each year. Approximately half of all cancer cases metastasize, contributing to the leading cause of cancer pain. This book emphasizes that every person's cancer is unique, and every person has the right to be well-informed and to be the decision-maker in planning treatment to offer the best possible quality of life. Each book in the "QuickFACTS" series is both comprehensive and a quick read, with highlighted cover tabs for quick reference of specific topics. It covers everything from risk factors to living well after cancer treatment. It provides critical questions to ask the healthcare team. It educates and empowers patients right from the start. It is completely updated with the latest patient... |
 |
Metastasis of Prostate Cancer (Cancer Metastasis - Biology and Treatment) by Richard J. Ablin (Author), Richard J. Ablin (Editor), Malcolm D. Mason (Editor) This volume brings together the key research issues in clinical and laboratory science relating to metastasis in prostate cancer. It is especially suitable for those in the field, whether physicians and/or scientists, and whether in active research or in training, who wish to broaden their understanding, with regard to their own discipline, and also to another. It is also a resource for those whose research is in metastasis, but in diseases other than prostate cancer. The intention of this volume is to help to empower those who seek to further exploit the potential for translational research in this field. Written by a team of internationally recognised experts, the scope ranges from the most fundamental aspects of the molecular biology of metastasis, to the patient in the clinic. The... |
 |
Bone Metastasis (Cancer Drug Discovery and Development) by Gurmit Singh (Editor), Shafaat A. Rabbani (Editor) A state-of-the-art review of the molecular underpinnings of bone-seeking cancers, current treatment approaches for them, and future therapeutic strategies. The authors illuminate the role of various autocrine, paracrine, and immunological factors involved in the progression and establishment of bone metastases, highlighting the physiological processes that lead to bone degradation, pain, angiogenesis, and dysregulation of bone turnover. They also discuss the various strategies that appear to have promise and are currently deployed in treatment or are at the experimental stage. |
 |
2006 ANNUAL MEETING A.H.P.B.A DVD 09 AMERICAN HEPATO-PANCREATO-BILIARY ASSOCIATION/2006 Hepatology GENERAL POSTER SESSION: . The impact of margins on outcome following hepatic resection for colorrectal metastasis - Dr. Rowan Parks (UK) . IIC-Acetate in superior to 18F-Fluoroderyglucose (FDG) positron emisson tomography (PET) in evaluating patients with hepatocellular carcinoma - results of a pilot trial - Dr. C. Wright Pinson (USA) . Effect of extending-4 treatment in minimal islet mass transplant model in streptozotocin-induced diabetic mice - Dr. Davin Eckhoff (USA) . Clinical and economic validation of the international study group of pancreatic fistula (ISGPF) classification scheme - Dr. Claudio Bassi (Italy) GENERAL POSTER SESSION: . Extent of lymph node dissection and staging for extrahepatic cholangiocarcinomas -... |
|
Cancer Invasion and Metastasis: Biologic and Therapeutic Aspects by Garth L. Nicolson (Editor) | |
 |
Metastasis for 61 musicians (1954) Southwest German Radio Symphony Orchestra (Primary Contributor) |
|
Fundamental Aspects of Metastasis. by Leonard (ed) Weiss (Author) |
| © 2009 BrightSurf.com |